This 2016 study evaluates the utility of liquid biopsies in monitoring metastatic melanoma progression. By analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in blood samples, the research demonstrates that liquid biopsies can provide real-time insights into tumor dynamics, detect emerging resistance mutations, and assess treatment response. The
This 2016 review explores the role of methylated circulating tumor DNA (ctDNA) as a non-invasive biomarker in cancer prognosis and treatment monitoring. ctDNA, detectable in plasma or serum, reflects tumor-specific genetic and epigenetic alterations, including aberrant DNA methylation patterns. These methylation changes are often consistent across patients, making them reliable
This article discusses the emerging field of liquid biopsy, focusing on the detection of circulating tumor DNA (ctDNA) in the bloodstream as a non-invasive method for cancer diagnosis and monitoring. The review highlights the advantages of liquid biopsy over traditional tissue biopsies, including its ability to capture tumor heterogeneity, monitor
This study explores the use of faecal calprotectin (FC) measurement as a non-invasive biomarker for diagnosing and managing inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Elevated FC levels correlate with active disease and can help distinguish IBD from other gastrointestinal conditions like irritable bowel syndrome
